Achieve Life Sciences Inc ACHV

$7.19 +0.34 (4.96%)

Valuation

Market cap
704,879,000
Revenue TTM
$0
Net income TTM
$-54,650,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
-0.60

Trading

Volume
1,374,500
Avg volume
1,452,600
Day's range
$6.90 – $7.23
Shares out
102,902,000
Stochastic %K
96%
Beta
2.30
Analysts
Strong Sell
Price target
$14.36

Price

Company profile

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD an...

Show more

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.

Industry
Biotechnology
Sector
Healthcare
Phone
604 210 2217
Website
https://www.achievelifesciences.com
Address
22722 29th Dr. SE, Suite 100, Bothell, United States

Latest news

Stocktwits

bobtheknob Oct 29, 3:59 PM
$ACHV regained 20 day moving average support, next target 50 day 💪
1 replies
ecoethcon Oct 22, 7:30 PM
$ACHV I have a mixed reaction on the recent study released by Achieve. As an investor and one who is concerned about the quality of health care it is amazing news. As a citizen it is disappointing that after all these years in which the data has been uniformly positive on both efficacy and safety fronts that this is taking so long. Gatekeeping comes to mind and it goes right to the heart of how FDA is funded and how it operates. So many people should have been given the opportunity and so many lives could have been saved...the last few years things have been held up by very fixable technicalities. I will just keep investing here and with others do what we can to improve the system...
2 replies
drdoctor7 Oct 21, 8:44 PM
$ACHV Vaping Data. The ORCA-OL enrolled 61 adults who vaped exclusively. At the end of the year, 24.6% achieved biochemical evidence of cessation. To my knowledge, these are the first data from a hard-to-treat vaping population by inclusion criteria. Furthermore, the trial continued to report a very favourable side effect profile with increased and prolonged exposure to cytisinicline. Very positive!
1 replies
markwall Oct 21, 1:17 PM
$ACHV On October 21, 2026, Achieve Life Sciences presented new 52-week efficacy and safety data for cytisinicline from its open-label ORCA-OL clinical trial at the CHEST 2026 Annual Meeting. The trial evaluated adults who had continued smoking or vaping daily despite prior participation in earlier short-term cytisinicline clinical trials (such as ORCA-2, ORCA-3, or ORCA-1). Participants received 3 mg of cytisinicline three times daily along with behavioral support for up to 52 weeks to study the effects of continuous, long-term exposure and retreatment.
2 replies
Rayvio_News_Filter Oct 21, 12:32 PM
$ACHV 🏥 Achieve Life Sciences, Inc. presented 52-week ORCA-OL results showing 39% of participants new to cytisinicline had quit smoking or vaping at one year. Market-relevant event
0 replies
inmarketswetrust Oct 20, 11:29 PM
$ACHV don’t think all the younger vapers think they have a problem yet- they think they’re doing the healthier thing by not smoking- for older smokers, who have been smoking for decades, the best quit rate on the first attempt using achieve drug is still only 32%. Will play a bump in share price around the re submission of NDA by end of year tho. Plus having heavy hitters from VRNA now in key leadership positions gives me hope. Just don’t see nicotine addiction going away. Still a decent catalyst play for now
1 replies
AyemanAyeman Oct 20, 8:35 PM
$ACHV why go down
0 replies
DoofyInvests Oct 16, 9:30 PM
$ACHV Lots of tickers down heavy today. XBI down nearly 5%. This dip is more related to overall market sentiment than anything related to ACHV explicitly.
2 replies